Analyzing Novogen Limited (NVGN) and Compugen (CGEN)

Novogen Limited (NASDAQ: NVGN) and Compugen (NASDAQ:CGEN) are both small-cap healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their analyst recommendations, profitability, risk, valuation, earnings, institutional ownership and dividends.

Risk & Volatility

Novogen Limited has a beta of -0.3, suggesting that its share price is 130% less volatile than the S&P 500. Comparatively, Compugen has a beta of 0.64, suggesting that its share price is 36% less volatile than the S&P 500.


This table compares Novogen Limited and Compugen’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Novogen Limited -6,144.93% -45.42% -31.89%
Compugen -4,425.00% -57.69% -50.83%

Analyst Recommendations

This is a summary of current ratings and recommmendations for Novogen Limited and Compugen, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Novogen Limited 0 0 1 0 3.00
Compugen 0 0 1 0 3.00

Novogen Limited presently has a consensus price target of $5.00, suggesting a potential upside of 64.09%. Compugen has a consensus price target of $14.00, suggesting a potential upside of 330.77%. Given Compugen’s higher possible upside, analysts clearly believe Compugen is more favorable than Novogen Limited.

Valuation & Earnings

This table compares Novogen Limited and Compugen’s revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio EBITDA Earnings Per Share Price/Earnings Ratio
Novogen Limited $3.80 million 3.87 -$8.41 million N/A N/A
Compugen $123,000.00 1,351.02 -$33.14 million ($0.67) -4.85

Novogen Limited has higher revenue and earnings than Compugen.

Institutional & Insider Ownership

6.4% of Novogen Limited shares are owned by institutional investors. Comparatively, 17.5% of Compugen shares are owned by institutional investors. 1.0% of Novogen Limited shares are owned by insiders. Comparatively, 9.5% of Compugen shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.


Compugen beats Novogen Limited on 6 of the 10 factors compared between the two stocks.

Novogen Limited Company Profile

Novogen Limited (Novogen) is an oncology biotechnology company, which is focused on developing cancer treatments. The Company is primarily engaged in pharmaceutical research and development. Novogen has two drug technology platforms (the Superbenzopyran (SBP) technology and Anti-tropomyosin (ATM)) yielding various drug candidates across a range of oncology indications. The Company’s product candidates include Cantrixil (TRX-E-002-1), Anisina (ATM-3507) and Trilexium (TRX-E-009-1). The Company’s target indication for Cantrixil is ovarian cancer, and Diffuse Intrinsic Pontine Glioma (DIPG) for Trilexium. The initial target pediatric indication for Anisina is neuroblastoma. Cantrixil is the lead development candidate arising from its SBP technology. Anisina is an approach to chemotherapy that targets the cancer cells’ actin cytoskeleton. Trilexium (TRX-E-009-1) is its second lead SBP drug candidate. It focuses on various cancers, including melanoma and prostate cancer.

Compugen Company Profile

Compugen Ltd. is a therapeutic discovery company. The Company focuses on infrastructure to discover drug targets and develop therapeutics. The Company is engaged in the research, development and commercialization of therapeutic and product candidates. The Company’s pipeline primarily consists of early and preclinical stage immuno-oncology programs based on drug targets discovered by the Company, primarily immune checkpoint and myeloid protein target candidates. These programs are focused on the development of cancer immunotherapy drugs with potential to harness the immune system to provide treatment solutions in areas of unmet medical needs in various cancer types and patient populations, both as monotherapy and in combination with other drugs. Its pipeline also includes a preclinical stage fusion protein autoimmune product candidate. Its fields of focus are oncology and immunology, with emphasis on its discovery capabilities on immuno-oncology.

Receive News & Ratings for Novogen Limited Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novogen Limited and related companies with's FREE daily email newsletter.

Latest News

Leave a Reply